CompletedPhase 2

A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

United States223 participantsStarted 2011-10

Plain-language summary

To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer * Received at least one prior platinum based chemotherapy regimen * Platinum-resistant or refractory * Eligible for weekly paclitaxel * Adequate liver and kidney function * 18 years of age or above Exclusion Criteria: * Evidence of any other active malignancy * History of severe allergic reactions to paclitaxel or other drugs formulated in Cremophor®EL

What they're measuring

Progression Free Survival

Timeframe: Time from first dose to date of progression, the longest time frame of 3.9 years

Trial details

NCT IDNCT01447706

SponsorMerrimack Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2013-09

Results submitted2016-02-17

View on ClinicalTrials.gov More Epithelial Ovarian Cancer trials